Overview on Interstitial Lung Disease (ILD), including causes, symptoms, diagnostics, and management strategies. For more information, please contact us: 9779030507.
This document discusses interstitial lung diseases (ILD), also known as diffuse parenchymal lung diseases (DPLD). It provides the following key points:
1. ILD can be caused by over 200 diseases that result in damage to the lung interstitium. Common causes include occupational exposures, collagen vascular diseases, drugs, infections, and idiopathic interstitial pneumonias.
2. Accurately diagnosing ILD requires a multidisciplinary approach including clinical evaluation, radiology such as high-resolution CT, and pathology including surgical lung biopsy.
3. Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and
Interstitial lung diseases (ILDs) are a group of diffuse parenchymal lung diseases featuring non-infective infiltrations of the lung interstitium and alveoli. Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of ILD with characteristic histopathological patterns of usual interstitial pneumonia (UIP) or nonspecific interstitial pneumonia (NSIP) on lung biopsy. Other ILDs include sarcoidosis, hypersensitivity pneumonitis, and ILDs associated with connective tissue diseases. Accurate diagnosis involves correlating clinical, radiological, and histopathological findings.
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease characterized by airflow limitation that is usually progressive. The airflow limitation is caused by an abnormal inflammatory response of the lungs to noxious particles or gases, most commonly from cigarette smoking. COPD poses a significant global disease burden and is projected to be the third leading cause of death worldwide by 2020. Key factors in the diagnosis of COPD include a history of exposure to risk factors, symptoms of cough, sputum production, and dyspnea, and confirmation of airflow limitation via spirometry testing. Management involves smoking cessation, bronchodilators, pulmonary rehabilitation, oxygen therapy, and in some cases lung surgery.
This gentleman has COPD exacerbation with underlying chronic bronchitis and emphysema due to long term smoking.
COPD is characterized by chronic inflammation of the lungs and narrowing of the airways due to long term exposure to noxious particles like cigarette smoke. In chronic bronchitis, there is chronic inflammation of the bronchi with excess mucus production leading to cough. In emphysema, there is damage to alveolar walls leading to loss of elasticity of lungs.
Pathologically in chronic bronchitis, there would be inflammation, thickening and scarring of bronchial walls with hyperplasia of mucus glands. In emphysema, there would be destruction of alveolar walls leading
Presentation on Treatment of Bronchial Asthma | Jindal Chest ClinicJindal Chest Clinic
Bronchial asthma is a lung disease characterized by inflammation, narrowing, swelling of airways, and increased mucus production, making it difficult to breathe. This Presentation gives an overview on "Treatment of Bronchial Asthma" including management, diagnosis, symptoms, Complications, etc. For more information, please contact us: 9779030507.
The document discusses interstitial lung diseases (ILDs), including:
- ILDs are a group of non-infectious diseases affecting the lungs' interstitium and alveoli.
- Classification is based on clinical, radiological, and pathological features. Idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP) are examples.
- Diagnosis involves clinical history, imaging like CT, lung function tests, and sometimes biopsy. Prognosis and treatment vary depending on the specific ILD.
This document summarizes information about the respiratory system, including acute bronchitis, tuberculosis, lung cancer, asthma, and COPD. It discusses the causes, symptoms, diagnostic tests, and treatments for each condition. For tuberculosis, it specifically notes that it is caused by Mycobacterium tuberculosis and remains a major cause of disability and death worldwide. It also discusses multidrug-resistant and extensively drug-resistant strains of TB.
This document discusses interstitial lung diseases (ILD), also known as diffuse parenchymal lung diseases (DPLD). It provides the following key points:
1. ILD can be caused by over 200 diseases that result in damage to the lung interstitium. Common causes include occupational exposures, collagen vascular diseases, drugs, infections, and idiopathic interstitial pneumonias.
2. Accurately diagnosing ILD requires a multidisciplinary approach including clinical evaluation, radiology such as high-resolution CT, and pathology including surgical lung biopsy.
3. Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and
Interstitial lung diseases (ILDs) are a group of diffuse parenchymal lung diseases featuring non-infective infiltrations of the lung interstitium and alveoli. Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of ILD with characteristic histopathological patterns of usual interstitial pneumonia (UIP) or nonspecific interstitial pneumonia (NSIP) on lung biopsy. Other ILDs include sarcoidosis, hypersensitivity pneumonitis, and ILDs associated with connective tissue diseases. Accurate diagnosis involves correlating clinical, radiological, and histopathological findings.
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease characterized by airflow limitation that is usually progressive. The airflow limitation is caused by an abnormal inflammatory response of the lungs to noxious particles or gases, most commonly from cigarette smoking. COPD poses a significant global disease burden and is projected to be the third leading cause of death worldwide by 2020. Key factors in the diagnosis of COPD include a history of exposure to risk factors, symptoms of cough, sputum production, and dyspnea, and confirmation of airflow limitation via spirometry testing. Management involves smoking cessation, bronchodilators, pulmonary rehabilitation, oxygen therapy, and in some cases lung surgery.
This gentleman has COPD exacerbation with underlying chronic bronchitis and emphysema due to long term smoking.
COPD is characterized by chronic inflammation of the lungs and narrowing of the airways due to long term exposure to noxious particles like cigarette smoke. In chronic bronchitis, there is chronic inflammation of the bronchi with excess mucus production leading to cough. In emphysema, there is damage to alveolar walls leading to loss of elasticity of lungs.
Pathologically in chronic bronchitis, there would be inflammation, thickening and scarring of bronchial walls with hyperplasia of mucus glands. In emphysema, there would be destruction of alveolar walls leading
Presentation on Treatment of Bronchial Asthma | Jindal Chest ClinicJindal Chest Clinic
Bronchial asthma is a lung disease characterized by inflammation, narrowing, swelling of airways, and increased mucus production, making it difficult to breathe. This Presentation gives an overview on "Treatment of Bronchial Asthma" including management, diagnosis, symptoms, Complications, etc. For more information, please contact us: 9779030507.
The document discusses interstitial lung diseases (ILDs), including:
- ILDs are a group of non-infectious diseases affecting the lungs' interstitium and alveoli.
- Classification is based on clinical, radiological, and pathological features. Idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP) are examples.
- Diagnosis involves clinical history, imaging like CT, lung function tests, and sometimes biopsy. Prognosis and treatment vary depending on the specific ILD.
This document summarizes information about the respiratory system, including acute bronchitis, tuberculosis, lung cancer, asthma, and COPD. It discusses the causes, symptoms, diagnostic tests, and treatments for each condition. For tuberculosis, it specifically notes that it is caused by Mycobacterium tuberculosis and remains a major cause of disability and death worldwide. It also discusses multidrug-resistant and extensively drug-resistant strains of TB.
This document provides an overview of chronic obstructive pulmonary disease (COPD) including its definition, epidemiology, pathogenesis, clinical features, diagnosis and management according to global guidelines. It discusses COPD as a chronic inflammatory lung disease characterized by irreversible airflow limitation. Cigarette smoking is identified as the primary risk factor and pathogenesis involves an abnormal inflammatory response in the lungs to noxious particles or gases.
The document provides information on the management of COPD, including its goals, treatment steps, guidelines on smoking cessation, bronchodilators, inhalational treatments, complications, exacerbations, and pulmonary rehabilitation. The main goals of COPD treatment are symptomatic relief, prevention of complications, and reduction in lung function decline. Treatment involves bronchodilators, inhaled corticosteroids, smoking cessation, and pulmonary rehabilitation. Complications include acute exacerbations, pulmonary hypertension, respiratory failure, and cor pulmonale.
The document discusses Chronic Obstructive Pulmonary Disease (COPD). It defines COPD as a common lung disease characterized by airflow limitation caused by exposure to noxious particles or gases. The main symptoms include dyspnea, cough, and sputum production. Smoking is the primary risk factor. The pathology involves chronic inflammation in the lungs leading to airflow limitation. Diagnosis is confirmed by spirometry showing persistent airflow limitation. Management involves smoking cessation, bronchodilators, anti-inflammatories, oxygen therapy, pulmonary rehabilitation, and treatment of exacerbations and comorbidities.
Chronic Obstructive Pulmonary Disease (COPD) is a common preventable respiratory disease characterized by persistent airflow limitation caused by airway and alveolar abnormalities due to significant exposure to noxious particles or gases. The document discusses the definition, epidemiology including risk factors, pathophysiology, clinical features, complications, staging, and management of COPD according to the GOLD guidelines. It also provides case scenarios and discusses approaches to diagnosing and differentiating COPD from other conditions.
This document discusses chronic kidney disease and its management. It defines chronic kidney disease as kidney damage and decreased kidney function for over 3 months. It then discusses the pathophysiology of chronic renal failure, noting the loss of nephrons and failure of kidney roles in fluid balance, waste excretion, and hormone regulation. Common causes of chronic kidney disease are listed, and the progression from initial insult to end stage renal disease is described. Diagnosis involves history, exam, and blood and urine tests to assess kidney function and check for underlying etiologies. Treatment focuses on slowing progression, managing complications, and preparing for renal replacement therapies like dialysis and transplantation.
Practical approach to interstitial lung diseases Hamdi Turkey
These lecture notes were prepared by Dr. Hamdi Turkey- Pulmonologist- Department of internal medicine - Taiz university
Do Not Forget To Visit Our Pages On Facebook on the following Links:
https://www.facebook.com/groups/569435236444761/
AND
https://www.facebook.com/groups/690331650977113/
Asthma is a chronic lung disease that causes recurring periods of wheezing, chest tightness, and coughing, often at night or early morning. It is triggered by exposure to various irritants and allergens that differ between individuals. While asthma has no cure, it can be controlled through avoiding triggers, taking short-term rescue medications for symptoms, and long-term control medications daily to prevent symptoms and exacerbations. Proper management requires learning one's personal triggers and working with a medical provider.
Interstitial lung disease (ILD) is a group of diseases causing fibrosis in the lungs, leading to stiffness and difficulty in breathing and oxygen delivery to the bloodstream. This presentation gives an overview on "Diagnosis of ILD". For more information, please contact us: 9779030507.
This document provides an overview of chronic obstructive pulmonary disease (COPD). It defines COPD as a preventable and treatable disease characterized by airflow limitation caused by cigarette smoking and exposure to other noxious particles. The document outlines the risk factors, pathogenesis, pathophysiology, symptoms, diagnosis, classification, and management of COPD. Spirometry is a key test for COPD diagnosis and assessment. The goals of treatment are to prevent progression, relieve symptoms, improve exercise tolerance, and prevent exacerbations.
1. COPD is a chronic inflammatory lung disease characterized by airflow limitation that is usually caused by long-term exposure to irritating gases or particulate matter, most commonly from cigarette smoking.
2. Diagnosis of COPD involves clinical evaluation of symptoms and medical history combined with lung function tests, particularly spirometry.
3. Current guidelines classify COPD severity into four stages based on lung function measurements and symptoms, and recommend treatments that include bronchodilators, corticosteroids, and supplemental oxygen for advanced disease.
The document discusses interstitial lung diseases (ILD), a broad category of lung disorders characterized by inflammation and scarring of the lungs. ILDs can have diverse causes and presentations. Symptoms include breathlessness, cough, and fatigue. Investigations involve imaging like chest X-rays and CT scans showing infiltrates and fibrosis. Management focuses on removing triggers, suppressing inflammation, and palliation. Treatment may include corticosteroids, immunosuppressants, oxygen therapy, and rehabilitation.
Childhood asthma - etiopathogenesis,clinical manifestations and evaluationLokanath Reddy Mummadi
This document provides an overview of childhood asthma including its definition, epidemiology, etiology, pathogenesis, clinical manifestations, diagnosis and evaluation. Some key points:
- Asthma is a chronic inflammatory airway disease characterized by wheezing, breathlessness, chest tightness and cough.
- Global prevalence has increased 50% per decade, with higher rates in Western countries and urban areas. India has an estimated prevalence of 3%.
- It results from an interaction between genetic and environmental factors such as viruses, allergens, air pollution and tobacco smoke.
- Pathogenesis involves chronic airway inflammation and remodeling driven by T helper 2 cells and eosinophils in response to triggers.
This document discusses approaches to asthma and newer modalities in treatment. It begins by defining asthma as a chronic airway inflammation disease characterized by variable respiratory symptoms. It then discusses triggers of asthma attacks and the pathophysiology involving immune cells like mast cells, basophils, and eosinophils. The document outlines the diagnostic approach including assessing symptoms, lung function testing, allergy testing, and trial of treatments. It also discusses managing asthma through a stepwise treatment approach based on symptom severity. Finally, it introduces several newer treatment modalities for asthma including allergen immunotherapy, anti-IgE therapy like Omalizumab, and long-acting bronchodilators.
This document discusses approaches to asthma and newer modalities in treatment. It begins by defining asthma as a chronic airway inflammation disease characterized by variable respiratory symptoms and airflow limitation. It then discusses asthma triggers and the pathophysiology involving T helper cells, cytokines, IgE, mast cells, and eosinophils. Diagnosis involves assessing symptoms, history, physical exam, pulmonary function tests, allergy testing, and response to treatment. Management follows a stepwise treatment approach adding or increasing controller medications as needed. Newer modalities discussed include allergen immunotherapy, anti-IgE therapy like omalizumab, anti-IL13 therapy, long-acting bronchodilators, and bronchial thermoplasty.
The document discusses respiratory disorders and focuses on asthma. It defines asthma as a condition where the airways become inflamed, narrow, and produce excess mucus, making breathing difficult. The document outlines the causes, types, pathogenesis, signs and symptoms, diagnosis, classification based on severity, complications, and treatment of asthma through medications and non-pharmacological methods. It also briefly discusses other respiratory disorders like COPD, bronchiectasis, and their causes, signs/symptoms, diagnosis, and treatment.
This document provides information on interstitial lung disease from a seminar presented by Ms. Saheli Chakraborty. It defines interstitial lung disease as progressive scarring of lung tissue. It discusses the objectives, introduction, definition, etiology, risk factors, pathophysiology, clinical manifestations, diagnostic evaluations, complications, management, nursing management, nursing diagnoses and common types of interstitial lung diseases including sarcoidosis, idiopathic pulmonary fibrosis, interstitial pneumonia, asbestosis and acute interstitial pneumonitis.
This document discusses chronic obstructive pulmonary disease (COPD), specifically bronchitis. It defines bronchitis as an inflammation of the bronchi in the lungs, usually due to infection. The two main types are acute bronchitis, which usually lasts a few weeks, and chronic bronchitis, which is a persistent cough for 3 months. Common causes are smoking, viruses like rhinovirus, and bacteria like streptococcus pneumoniae. Symptoms include cough, sputum production, wheezing, and shortness of breath. Treatment involves antibiotics, bronchodilators, corticosteroids, and airway clearance techniques.
This document discusses respiratory pathology and pathophysiology, focusing on major pulmonary diseases. It begins by outlining common presenting symptoms of pulmonary disease like cough, hemoptysis, dyspnea, and chest pain. It then examines specific conditions, including respiratory infections, pneumonias, tuberculosis, obstructive lung diseases like COPD and asthma, restrictive lung diseases, cystic fibrosis, and lung cancers. For each, it discusses etiology, pathophysiology, diagnosis, and treatment.
A 19-year old female college student with a history of persistent asthma and allergic rhinitis was admitted to the student health service overnight for increased shortness of breath, wheezing, poor exercise tolerance, and nasal stuffiness. She improved after receiving oxygen, bronchodilators, and corticosteroids. The document discusses asthma pathogenesis, diagnosis, treatment including pharmacotherapy and environmental control, and goals of chronic asthma management.
Thrombo-prophylaxis in Critical Care | Jindal chest clinicJindal Chest Clinic
Thrombo-prophylaxis used in critically ill patients who are either bleeding or are at high risk for bleeding. This presentationby Dr. Aditya Jindal on "Thrombo-prophylaxis in Critical Care". For more information, please contact: 9779030507.
More Related Content
Similar to Interstitial Lung Disease | Jindal Chest Clinics
This document provides an overview of chronic obstructive pulmonary disease (COPD) including its definition, epidemiology, pathogenesis, clinical features, diagnosis and management according to global guidelines. It discusses COPD as a chronic inflammatory lung disease characterized by irreversible airflow limitation. Cigarette smoking is identified as the primary risk factor and pathogenesis involves an abnormal inflammatory response in the lungs to noxious particles or gases.
The document provides information on the management of COPD, including its goals, treatment steps, guidelines on smoking cessation, bronchodilators, inhalational treatments, complications, exacerbations, and pulmonary rehabilitation. The main goals of COPD treatment are symptomatic relief, prevention of complications, and reduction in lung function decline. Treatment involves bronchodilators, inhaled corticosteroids, smoking cessation, and pulmonary rehabilitation. Complications include acute exacerbations, pulmonary hypertension, respiratory failure, and cor pulmonale.
The document discusses Chronic Obstructive Pulmonary Disease (COPD). It defines COPD as a common lung disease characterized by airflow limitation caused by exposure to noxious particles or gases. The main symptoms include dyspnea, cough, and sputum production. Smoking is the primary risk factor. The pathology involves chronic inflammation in the lungs leading to airflow limitation. Diagnosis is confirmed by spirometry showing persistent airflow limitation. Management involves smoking cessation, bronchodilators, anti-inflammatories, oxygen therapy, pulmonary rehabilitation, and treatment of exacerbations and comorbidities.
Chronic Obstructive Pulmonary Disease (COPD) is a common preventable respiratory disease characterized by persistent airflow limitation caused by airway and alveolar abnormalities due to significant exposure to noxious particles or gases. The document discusses the definition, epidemiology including risk factors, pathophysiology, clinical features, complications, staging, and management of COPD according to the GOLD guidelines. It also provides case scenarios and discusses approaches to diagnosing and differentiating COPD from other conditions.
This document discusses chronic kidney disease and its management. It defines chronic kidney disease as kidney damage and decreased kidney function for over 3 months. It then discusses the pathophysiology of chronic renal failure, noting the loss of nephrons and failure of kidney roles in fluid balance, waste excretion, and hormone regulation. Common causes of chronic kidney disease are listed, and the progression from initial insult to end stage renal disease is described. Diagnosis involves history, exam, and blood and urine tests to assess kidney function and check for underlying etiologies. Treatment focuses on slowing progression, managing complications, and preparing for renal replacement therapies like dialysis and transplantation.
Practical approach to interstitial lung diseases Hamdi Turkey
These lecture notes were prepared by Dr. Hamdi Turkey- Pulmonologist- Department of internal medicine - Taiz university
Do Not Forget To Visit Our Pages On Facebook on the following Links:
https://www.facebook.com/groups/569435236444761/
AND
https://www.facebook.com/groups/690331650977113/
Asthma is a chronic lung disease that causes recurring periods of wheezing, chest tightness, and coughing, often at night or early morning. It is triggered by exposure to various irritants and allergens that differ between individuals. While asthma has no cure, it can be controlled through avoiding triggers, taking short-term rescue medications for symptoms, and long-term control medications daily to prevent symptoms and exacerbations. Proper management requires learning one's personal triggers and working with a medical provider.
Interstitial lung disease (ILD) is a group of diseases causing fibrosis in the lungs, leading to stiffness and difficulty in breathing and oxygen delivery to the bloodstream. This presentation gives an overview on "Diagnosis of ILD". For more information, please contact us: 9779030507.
This document provides an overview of chronic obstructive pulmonary disease (COPD). It defines COPD as a preventable and treatable disease characterized by airflow limitation caused by cigarette smoking and exposure to other noxious particles. The document outlines the risk factors, pathogenesis, pathophysiology, symptoms, diagnosis, classification, and management of COPD. Spirometry is a key test for COPD diagnosis and assessment. The goals of treatment are to prevent progression, relieve symptoms, improve exercise tolerance, and prevent exacerbations.
1. COPD is a chronic inflammatory lung disease characterized by airflow limitation that is usually caused by long-term exposure to irritating gases or particulate matter, most commonly from cigarette smoking.
2. Diagnosis of COPD involves clinical evaluation of symptoms and medical history combined with lung function tests, particularly spirometry.
3. Current guidelines classify COPD severity into four stages based on lung function measurements and symptoms, and recommend treatments that include bronchodilators, corticosteroids, and supplemental oxygen for advanced disease.
The document discusses interstitial lung diseases (ILD), a broad category of lung disorders characterized by inflammation and scarring of the lungs. ILDs can have diverse causes and presentations. Symptoms include breathlessness, cough, and fatigue. Investigations involve imaging like chest X-rays and CT scans showing infiltrates and fibrosis. Management focuses on removing triggers, suppressing inflammation, and palliation. Treatment may include corticosteroids, immunosuppressants, oxygen therapy, and rehabilitation.
Childhood asthma - etiopathogenesis,clinical manifestations and evaluationLokanath Reddy Mummadi
This document provides an overview of childhood asthma including its definition, epidemiology, etiology, pathogenesis, clinical manifestations, diagnosis and evaluation. Some key points:
- Asthma is a chronic inflammatory airway disease characterized by wheezing, breathlessness, chest tightness and cough.
- Global prevalence has increased 50% per decade, with higher rates in Western countries and urban areas. India has an estimated prevalence of 3%.
- It results from an interaction between genetic and environmental factors such as viruses, allergens, air pollution and tobacco smoke.
- Pathogenesis involves chronic airway inflammation and remodeling driven by T helper 2 cells and eosinophils in response to triggers.
This document discusses approaches to asthma and newer modalities in treatment. It begins by defining asthma as a chronic airway inflammation disease characterized by variable respiratory symptoms. It then discusses triggers of asthma attacks and the pathophysiology involving immune cells like mast cells, basophils, and eosinophils. The document outlines the diagnostic approach including assessing symptoms, lung function testing, allergy testing, and trial of treatments. It also discusses managing asthma through a stepwise treatment approach based on symptom severity. Finally, it introduces several newer treatment modalities for asthma including allergen immunotherapy, anti-IgE therapy like Omalizumab, and long-acting bronchodilators.
This document discusses approaches to asthma and newer modalities in treatment. It begins by defining asthma as a chronic airway inflammation disease characterized by variable respiratory symptoms and airflow limitation. It then discusses asthma triggers and the pathophysiology involving T helper cells, cytokines, IgE, mast cells, and eosinophils. Diagnosis involves assessing symptoms, history, physical exam, pulmonary function tests, allergy testing, and response to treatment. Management follows a stepwise treatment approach adding or increasing controller medications as needed. Newer modalities discussed include allergen immunotherapy, anti-IgE therapy like omalizumab, anti-IL13 therapy, long-acting bronchodilators, and bronchial thermoplasty.
The document discusses respiratory disorders and focuses on asthma. It defines asthma as a condition where the airways become inflamed, narrow, and produce excess mucus, making breathing difficult. The document outlines the causes, types, pathogenesis, signs and symptoms, diagnosis, classification based on severity, complications, and treatment of asthma through medications and non-pharmacological methods. It also briefly discusses other respiratory disorders like COPD, bronchiectasis, and their causes, signs/symptoms, diagnosis, and treatment.
This document provides information on interstitial lung disease from a seminar presented by Ms. Saheli Chakraborty. It defines interstitial lung disease as progressive scarring of lung tissue. It discusses the objectives, introduction, definition, etiology, risk factors, pathophysiology, clinical manifestations, diagnostic evaluations, complications, management, nursing management, nursing diagnoses and common types of interstitial lung diseases including sarcoidosis, idiopathic pulmonary fibrosis, interstitial pneumonia, asbestosis and acute interstitial pneumonitis.
This document discusses chronic obstructive pulmonary disease (COPD), specifically bronchitis. It defines bronchitis as an inflammation of the bronchi in the lungs, usually due to infection. The two main types are acute bronchitis, which usually lasts a few weeks, and chronic bronchitis, which is a persistent cough for 3 months. Common causes are smoking, viruses like rhinovirus, and bacteria like streptococcus pneumoniae. Symptoms include cough, sputum production, wheezing, and shortness of breath. Treatment involves antibiotics, bronchodilators, corticosteroids, and airway clearance techniques.
This document discusses respiratory pathology and pathophysiology, focusing on major pulmonary diseases. It begins by outlining common presenting symptoms of pulmonary disease like cough, hemoptysis, dyspnea, and chest pain. It then examines specific conditions, including respiratory infections, pneumonias, tuberculosis, obstructive lung diseases like COPD and asthma, restrictive lung diseases, cystic fibrosis, and lung cancers. For each, it discusses etiology, pathophysiology, diagnosis, and treatment.
A 19-year old female college student with a history of persistent asthma and allergic rhinitis was admitted to the student health service overnight for increased shortness of breath, wheezing, poor exercise tolerance, and nasal stuffiness. She improved after receiving oxygen, bronchodilators, and corticosteroids. The document discusses asthma pathogenesis, diagnosis, treatment including pharmacotherapy and environmental control, and goals of chronic asthma management.
Similar to Interstitial Lung Disease | Jindal Chest Clinics (20)
Thrombo-prophylaxis in Critical Care | Jindal chest clinicJindal Chest Clinic
Thrombo-prophylaxis used in critically ill patients who are either bleeding or are at high risk for bleeding. This presentationby Dr. Aditya Jindal on "Thrombo-prophylaxis in Critical Care". For more information, please contact: 9779030507.
Physiology of the Respiratory System | Jindal chest clinicJindal Chest Clinic
Respiratory system is the system in which the organs and structures in body that allow to breathe. This presentation gives an overview on "Physiology of the Respiratory System" including: non respiratory functions, air conditioning, warming and humidfying, immune functions, functions of cilia, metabolic functions, etc. For more information please contact us: 9779030507.
Molecular Diagnosis of Tuberculosis by Dr. Aditya Jindal | Jindal Chest ClinicJindal Chest Clinic
Analyzing DNA or RNA sequences to spot warning signs of possible diseases is the process of molecular diagnostics, commonly referred to as molecular pathology. This presentation by Dr. Aditya Jindal, gives an overview on "Molecular Diagnosis of Tuberculosis". For more information, please contact us: 9779030507.
A difficult airway is a clinical situation in which a medical professional with training in airway management finds it difficult to use the recommended techniques. This presentation gives an overview on the topic "Difficult airway Management" including: difficult mask ventilation, preoxygenation, thyromental distance, laryngoscopy, cricothirotomy, etc. For more information, please contact us: 9779030507.
Difficult airway in ICU by Dr. Aditya Jindal | JIndal Chest ClinicJindal Chest Clinic
A difficult airway is a clinical situation in which a medical professional with training in airway management finds it difficult to use the recommended techniques. This presentation gives an overview on the topic "Difficult airway in ICU". For more information, please contact us: 9779030507.
Tuberculosis pathophysiology and diagnosis | Jindal Chest ClinicJindal Chest Clinic
Tuberculosis is an infectious lung disease caused by bacteria, spreading through the air through coughing, sneezing, or spit. It is preventable and curable. This presentation gives an overview on "Tuberculosis pathophysiology and diagnosis". For more information, please contact us: 9779030507.
Silicosis in India: Defining the problem and developing solutions | By Dr. S....Jindal Chest Clinic
Silicosis is a lung disease caused by inhaling small particles of silica, a common mineral found in sand, quartz, and rock, primarily affecting workers in construction and mining industries. For more information, please contact us: 9779030507.
Overview on "Pulmonary Vasculitis" including its: symptoms, diagnosis, pathology, risk factors, management, treatment, etc. For more information, please contact us: 9779030507.
Treatment of ILDs by Dr. S.K Jindal | JIndal Chest ClinicJindal Chest Clinic
Interstitial lung disease (ILD) refers to a variety of diseases causing fibrosis in the lungs, leading to stiffness and difficulty in breathing and oxygen delivery to the bloodstream. This presentation gives an overview on "Treatment of ILD". For more information, please contact us: 9779030507.
Asthma is the most frequent chronic illness in children and is a common noncommunicable disease (NCD) that affects both adults and children. Coughing, wheezing, chest tightness, and shortness of breath are among the symptoms. This presentation target therapies for Asthma including its clinical use, etc. For more information, please contact us: 9779030507.
Allergic bronchopulmonary aspergillosis (ABPA) is a lung fungal infection caused by a hypersensitivity reaction to Aspergillus fumigatus antigens after colonization into the airways. This presentation gives an overview on "Epidemiology of ABPA" including ABPA prevalence, treatment, etc. For more information, please contact us: 9779030507.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
2. Interstitial Lung Disease
Diseases of lung interstitium
Not a single disease – over 250 different diseases with similar clinical
and/or radiological features
Also known as : Diffuse Parenchymal Lung Disease or Diffuse Lung
disease because of Involvement of air spaces , vessels, airways, ?pleura -
i.e. diffuse involvement
Idiopathic pulmonary fibrosis (IPF) or Idiopathic Interstitial
Pneumonias (IIPs) are sometimes used synonymously with ILD
3.
4. Characteristics
Common clinical, radiological, physiological and histo pathologic
features
Hetero genous conditions
- Inflammatory
- Granulomatous
- Infections
- Depositions
- Oedema
5. Causes and Pathogenesis
Exact etiology, not know – Idiopathic
Secondary to other known causes
Inflammation, damage and fibrosis
Repair mechanisms (for inflammation) - aberrant
Diffuse involvement
Progressive
14. DIAGNOSIS
Clinical features
Laboratory investigations: Hematological, biochemical,
immunological etc.
Radiology: CXR, HRCT
Pulmonary function tests
Bronchoscopy: BAL, lung biopsy
Surgical lung biopsy
15. Diagnosis Issues
1. Diffuse vs. Local
2. Primary vs. Secondary
3. Cause of secondary ILD
4. Acute vs Chronic
5. Disease activity and progression
6. Responsive vs Nonresponsive
(to tmt)
7. Presence of complications
20. RADIOLOGICAL STUDIES
1. What is most helpful?
Diagnosis
Disease extent
Progression
2. Radiological findings: distribution and pattern
3. Correlation
4. Cost-effectiveness
23. 5. Hilar / mediastinal LN
Sarcoidosis
Lymphoma / Lymphangitis
6. Pneumothorax
Histocytosis X / LAM
7. Kerley B lines
8. Normal CXR
24. HIGH RESOLUTION CT
Better resolution / more accuracy
Earlier detection
Better assessment of extent and distribution
Occult adenopathy
Selection of biopsy site
25. PULM. FUNCTION TEST
1. Restrictive pattern
Reduced TLC, VC
FRC and RV
2. Flow rates: Reduced due to decreased VC
. Obstructive/mixed pattern :
smoking/other causes
3. Compliance : Low
4. DLCO – Reduced
5. Blood gases
26. BRONCHO ALVEOLAR LAVAGE
1. Nonspecific
2. Narrow down diff. diagnosis
3. Defines stage of disease
4. Assessment of progression
5. Assessment of treatment response
29. Objectives of Treatment of ILDs
1. Symptomatic relief
2. Slow down disease progression
3. Prevent/ Treat complications
4. Prolong survival
5. Improve Quality of Life
6. Prevent drug-induced problems
7. End of Life Care
30. Treatment Principles
I. Secondary ILDs
Treatment of ILD of a known primary cause essentially comprises
the treatment of the primary disorder.
Symptomatic
Anti-inflammatory
Supportive
II. Primary ILD (Idiopathic Interstitial Pneumonias) and Pulmonary
Fibrosis
31. Treatment of IIP/IPF
Of all IIPs, Idiopathic Pulmonary Fibrosis (IPF) i.e. U.I.P. is the
most common form.
It is associated with an extremely poor prognosis for survival in
most patients.
Life expectancy after diagnosis varies, but is on average less than 5
years.
32. Current Drug Treatment
1. Corticosteroids
2. Immunosuppressive drugs: Azathioprine,
Cyclophosphamide, Cyclosporine
3. Antifibrotic drugs: Pirfenidone, Colchicine, D-
penicillamine, Pentoxyfylline
4. Anti-oxidants: N. Acetyl-cysteine
33. Supportive Treatment
1. Underlying cause – Identification and management
2. Oxygen therapy
3. Management of pulmonary hypertension and cardiac failure
Pulm. Vasodilators
Diuretics
4. Antibiotics for infections
5. Miscellaneous
34. End Stage Disease
1. Lung Transplantation
2. Palliative End of Life Care
Domicilliary Oxygen
Symptomatic relief
Discontinuation of steroids and immunosuppressive drugs